GlassScriptPhysician profile
Holly A Parker
NPI 1952713356
$5,067.54
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,211 · 2023: $2,774 · 2024: $82.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,685 · Travel and Lodging: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,685.35 |
| Travel and Lodging | $170.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,620.29 | 2022-2023 | Percept PC Brainsense |
| Acadia Pharmaceuticals INC | $798.17 | 2022-2023 | Nuplazid |
| Abbvie INC. | $421.22 | 2022-2023 | |
| Abbott Laboratories | $405.73 | 2023 | Infinity, Proclaim |
| Merz Pharmaceuticals, LLC | $355.38 | 2022-2023 | Xeomin |
| Amneal Pharmaceuticals LLC | $334.87 | 2023 | Rytary |
| Neurocrine Biosciences, INC. | $228.57 | 2022-2023 | Ingrezza, Ongentys |
| Supernus Pharmaceuticals, INC. | $188.54 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $178.87 | 2023 | Austedo Xr, Austedo |
| Avion Pharmaceuticals | $109.67 | 2022-2023 | Dhivy |
| Ipsen Biopharmaceuticals, INC | $79.44 | 2022-2023 | Dysport |
| Mdd US Operations, LLC | $73.59 | 2023-2024 | Apokyn |
| Acorda Therapeutics, INC | $65.04 | 2023 | Inbrija |
| Kyowa Kirin, INC. | $57.48 | 2022-2023 | Nourianz |
| Ge Healthcare | $37.05 | 2022-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $29.26 | 2024 | Impella |
| Corium, LLC | $22.50 | 2022 | |
| Biogen, INC. | $18.81 | 2023 | Spinraza |
| Lundbeck LLC | $17.00 | 2023 | Rexulti |
| Azurity Pharmaceuticals, INC. | $16.32 | 2023 | Horizant |
| Sumitomo Pharma America, INC. | $9.74 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.